Interleukin Genetics Inc., a Waltham company that develops health products based on genetic research, faces delisting from the New York Stock Exchange Alternext US LLC.
Interleukin announced that it has received a notice from NYSE saying it is out of compliance with the exchange’s guidelines because its stockholders’ equity is less than $6 million and it has had losses from continuing operations and net losses in the past five years. The company said its stockholders’ equity was about $5.9 million as of September.
To maintain its listing the company can submit a plan by Jan. 23 explaining how it could get into compliance with the standards. Interleukin said it is now developing such a plan.
